BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.

Strinic D, Belosic Halle Z, Luetic K, Nedic A, Petrovic I, Sucic M, Zivanovic Posilovic G, Balenovic D, Strbe S, Udovicic M, Drmic D, Stupnisek M, Lovric Bencic M, Seiwerth S, Sikiric P

Life sciences7 Aug 2017Cited by 35 (Europe PMC)

PMID28797793DOI10.1016/j.lfs.2017.08.006PepBankPUB-28797793

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats given neuroleptics or prokinetics, BPC‑157 rapidly and permanently counteracted QTc prolongation.
In plain wordsIn rats given neuroleptics or prokinetics, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc interval prolongation induced by neuroleptics and prokinetics
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Summary
Thus, BPC 157 rapidly and permanently counteracts the QTc prolongation induced by neuroleptics and prokinetics.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779301
02AnimalAnimal study (in vivo)Efficacy outcome
In rats given haloperidol, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given haloperidol, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by haloperidol
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779302
03AnimalAnimal study (in vivo)Efficacy outcome
In rats given fluphenazine, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given fluphenazine, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by fluphenazine
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779303
04AnimalAnimal study (in vivo)Efficacy outcome
In rats given clozapine, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given clozapine, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by clozapine
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779304
05AnimalAnimal study (in vivo)Efficacy outcome
In rats given olanzapine, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given olanzapine, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by olanzapine
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779305
06AnimalAnimal study (in vivo)Efficacy outcome
In rats given quetiapine, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given quetiapine, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by quetiapine
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779306
07AnimalAnimal study (in vivo)Efficacy outcome
In rats given sulpiride, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given sulpiride, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by sulpiride
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779307
08AnimalAnimal study (in vivo)Efficacy outcome
In rats given metoclopramide, BPC‑157 counteracted QTc prolongation.
In plain wordsIn rats given metoclopramide, BPC‑157 counteracted the lengthening of the QTc interval compared with saline.
Peptide
BPC-157
Outcome
DecreaseQTc prolongation induced by metoclopramide
Study
ratn: not reported in source
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
10 µg/kg and 10 ng/kg · intraperitoneal · 7 daysAs given in this study (rat).
Source sentences
Title
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.
1 context sentence(design, population, supporting numbers)
Summary · context
rats were given a BPC 157 regimen once daily over seven days (10μg, 10ng/kg ip)
Report a problemFND-2879779308

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.